Images List Premium Download Classic

Allergy

Allergy-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Monoclonal antibody against muramyl peptides in prevention and treatment of immune-mediated diseases
Agency For Science, Technology And Research
November 30, 2017 - N°20170342136

Disclosed are methods of treating an autoimmune or inflammatory disease using a composition comprising an isolated antibody or an antigen-binding fragment or variant thereof that is capable of binding to muramyl peptide, derivative, analog or salt thereof, wherein said muramyl peptide comprises muramic acid and an amino acid selected from the group consisting of alanine, isoglutamine, glutamic acid and a ...
Allergy treatment kit
Agency For Science, Technology And Research
November 30, 2017 - N°20170340403

A portable emergency treatment kit for allergic and anaphylactic reactions. The kit comprises a carry case comprising a first panel and a second panel detachably connected together by a fastening member such as a zipper unit. A plurality of compartments on the inner face of the panels housing at least one oropharyngeal airway device, epinephrine injection, histamine h2 receptor antagonist ...
Vista regulatory t cell mediator protein, vista binding agents and use thereof
The Trustees Of Dartmouth College
November 23, 2017 - N°20170334990

The present invention relates to a novel regulatory t cell protein. This protein, designated pd-l3 or vista resembles members of the pd-l1 family, identified a novel and structurally-distinct, ig-superfamily inhibitory ligand, whose extra-cellular domain bears homology to the b7 family ligand pd-l1. This molecule is designated as pd-l3 or vista or v-domain immunoglobulin suppressor of t cell activation (vista). Expression ...
Allergy Patent Pack
Download + patent application PDFs
Allergy Patent Applications
Download + Allergy-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Allergy-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Topical use of prg4 for treatment of allergy and symptoms of inflammation
The Trustees Of Dartmouth College
November 02, 2017 - N°20170312335

Disclosed are methods involving the therapeutic use of human prg4 (prg4) protein, to ameliorate the symptoms associated with allergies and/or respiratory infections.
Aerosol composition for the prevention of symptoms of metal induced allergy and a method of ...
The Trustees Of Dartmouth College
November 02, 2017 - N°20170311687

The embodiments herein disclose hypoallergenic, metal surface sealant clear aerosol composition to be used on metals (specifically jewelry) to prevent skin allergies and the process of tarnishing of metal. The method of synthesizing hypoallergenic metal surface sealant clear aerosol composition comprises the following steps. The paraloid-b-48 material (10. 59 wt %) is added to ethyl acetate (31. 77 wt %) slowly under constant agitation. The mixture ...
Anti-human vista antibodies and use thereof
The Trustees Of Dartmouth College
October 26, 2017 - N°20170306024

The invention provides agonistic anti-human vista antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic vista's suppressive effects on t cell immunity and thereby suppress t cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, gvhd, sepsis and transplant recipients. ...
Allergy Patent Pack
Download + patent application PDFs
Allergy Patent Applications
Download + Allergy-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Allergy-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Anti-human vista antibodies and use thereof
Immunext, Inc.
October 26, 2017 - N°20170306022

The invention provides agonistic anti-human vista antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic vista's suppressive effects on t cell immunity and thereby suppress t cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, gvhd, sepsis and transplant recipients. ...
Anti-human vista antibodies and use thereof
Immunext, Inc.
October 26, 2017 - N°20170306021

The invention provides agonistic anti-human vista antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic vista's suppressive effects on t cell immunity and thereby suppress t cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, gvhd, sepsis and transplant recipients. ...
Anti-human vista antibodies and use thereof
The Trustees Of Dartmouth College
October 26, 2017 - N°20170306020

The invention provides agonistic anti-human vista antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic vista's suppressive effects on t cell immunity and thereby suppress t cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, gvhd, sepsis and transplant recipients. ...
Anti-human vista antibodies and use thereof
Immunext, Inc.
October 26, 2017 - N°20170306019

The invention provides agonistic anti-human vista antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic vista's suppressive effects on t cell immunity and thereby suppress t cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, gvhd, sepsis and transplant recipients. ...
Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor
Immunext, Inc.
October 19, 2017 - N°20170298022

Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as h4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.
Methods and compositions involving recombinant hypoallergens
Immunext, Inc.
October 19, 2017 - N°20170296652

This disclosure describes recombinant hypoallergens and methods of treating allergy that involve administering a recombinant hypoallergen to a subject. Generally, the recombinant hypoallergen includes at least one amino acid modification compared to a corresponding wildtype allergen. As a result, the recombinant hypoallergen binds to ige that specifically binds to the allergen, but induces release of histamine from basophils to a ...
Immune system stimulating nutrition
Immunext, Inc.
October 19, 2017 - N°20170296563

Disclosed is a nutritional composition comprising a combination of non-digestible oligosaccharides and a product obtained by incubating an aqueous substrate by bifidobacteria and optionally a product obtained by incubating an aqueous substrate by s. Thermophilus. Said combination synergistically improves the immune system by stimulating the th1 response, and/or decreasing the th2 response, improving the vaccination response, improving the resistance ...
Allergy Patent Pack
Download + patent application PDFs
Allergy Patent Applications
Download + Allergy-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Allergy-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Composition for the prevention and/or treatment of allergy symptoms
Ntc S.r.l.
September 14, 2017 - N°20170258864

The present invention relates to a pharmaceutical composition or a food supplement composition and use thereof in the prevention and/or treatment of allergy symptoms, preferably allergic rhinitis and/or allergic conjunctivitis symptoms. In particular, the composition according to the invention comprises at least one slow release component comprising quercetin and at least one fast release component comprising an extract ...
Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
Oculeve, Inc.
August 24, 2017 - N°20170239459

Described here are devices, systems, and methods for treating one or more conditions, such as allergic rhinitis, non-allergic rhinitis, nasal congestion, ocular allergy, and/or symptoms associated with these conditions, by providing stimulation to nasal or sinus tissue. In some variations, the handheld devices may have a stimulator body and a stimulator probe having one or more nasal insertion prongs, ...
Methods and kits for screening transplant recipients and candidates
National Institute Of Transplantation Foundation
August 17, 2017 - N°20170234875

Methods and kits are provided for determining of immunoglobulin isotypes and subclasses in a subject. In general the subject is a human who is a transplant candidate recipient or recipient, has allergies, or has an autoimmune disease. The method involves analyzing a sample of a body fluid of a transplant candidate or recipient, allergy patient or autoimmune disease sufferer and ...
Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
Idera Pharmaceuticals, Inc.
August 17, 2017 - N°20170233741

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, ...
Antibody therapeutics that bind ctla4
Sorrento Therapeutics, Inc.
August 17, 2017 - N°20170233476

There is disclosed compositions and methods relating to or derived from anti-ctla4 antibodies. More specifically, there is disclosed fully human antibodies that bind ctla4, ctla4-antibody binding fragments and derivatives of such antibodies, and ctla4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, ...
An anti-cd45rc antibody for use as drug
UniversitÉ De Nantes
August 10, 2017 - N°20170226209

The invention relates to an isolated anti-cd45rc antibody for use in preventing or treating transplant rejection, autoimmune diseases, unwanted immune responses against proteins expressed in the course of gene therapy and/or therapeutic proteins, allergy as well as lymphoma or cancer which are associated with cd45rc+ cells. The invention relates to an isolated anti-cd45rc antibody for use ...
Nanoparticles for treatment of allergy
Allertein Therapeutics, Llc
August 10, 2017 - N°20170224801

The present invention encompasses the surprising finding that nanoparticle compositions can have beneficial effects on allergy even when prepared without a known specific allergy therapeutic. The present invention provides such nanoparticle compositions. In some embodiments, provided nanoparticles are associated with functional elements that cause the nanoparticles to mimic bacterial cells. The present invention encompasses the surprising finding that provided nanoparticles ...
Novel allergen
Phadia Ab
August 03, 2017 - N°20170219602

The invention relates to a novel horse allergen consisting of a heterodimeric protein having a first peptide chain and a second peptide chain together having an overall sequence identity of at least 70% with the combined sequences of seq id no:3 and seq id no: 4, as well as a single chain protein having an overall sequence identity of at least 70%, such ...
Loading